Impact of lysophosphatidylcholine on survival and function of UEA-1+acLDL+ endothelial progenitor cells in patients with coronary artery disease

Heart and Vessels

Volumn 30, Issue 1, 2015, Pages 115-125

  Hong, Seong Hun ^a   Jang, Hyun Hee ^a   Lee, So Ra ^a   Lee, Kyung Hye ^a   Woo, Jong Shin ^a   Kim, Jin Bae ^a   Kim, Woo Shik ^a   Min, Byung Il ^a,b   Cho, Ki Ho ^c   Kim, Kwon Sam ^a   Cheng, Xianwu ^d   Kim, Weon ^a,b  

^a Kyung Hee University   (South Korea)

^b Kyung Hee University College of Medicine   (South Korea)

^c Jaseng Hospital of Korean Medicine   (South Korea)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Coronary artery disease; Endothelial progenitor cell; Lysophosphatidylcholine; Pravastatin; Vulnerable plaque

Indexed keywords

ACETYL-LDL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; NOS3 PROTEIN, HUMAN; OXIDIZED LOW DENSITY LIPOPROTEIN; PLANT LECTIN; PRAVASTATIN; PROTEIN KINASE B; ULEX EUROPAEUS LECTINS;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL ADHESION; CELL CULTURE; CELL MOTION; CORONARY ARTERY DISEASE; DRUG EFFECTS; ENDOTHELIAL PROGENITOR CELL; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

APOPTOSIS; CELL ADHESION; CELL MOVEMENT; CELLS, CULTURED; CORONARY ARTERY DISEASE; ENDOTHELIAL PROGENITOR CELLS; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPROTEINS, LDL; LYSOPHOSPHATIDYLCHOLINES; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PLANT LECTINS; PRAVASTATIN; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84938072302     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-014-0473-z     Document Type: Article

References (55)

1. Rabbani R, Topol EJ (1999) Strategies to achieve coronary arterial plaque stabilization. Cardiovasc Res 41:402–417
2. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R (2010) Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 30:1282–1292
3. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA (2002) Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 105:1567–1572
4. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD (1990) Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 344:160–162
5. Hsieh CC, Yen MH, Liu HW, Lau YT (2000) Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cells: in comparison with oxidized LDL. Atherosclerosis 151:481–491
6. Gonçalves I, Edsfeldt A, Ko NY, Grufman H, Berg K, Björkbacka H, Nitulescu M, Persson A, Nilsson M, Prehn C, Adamski J, Nilsson J (2012) Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation. Arterioscler Thromb Vasc Biol 32:1505–1512
7. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967
8. Vasa M, Fichtlscherer S, Aicher A, Urbich C, Martin H, Zeiher AM, Dimmeler S (2001) Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89(1):E1–E7
9. Briguori C, Testa U, Riccioni R, Colombo A, Petrucci E, Condorelli G, Mariani G, D’Andrea D, De Micco F, Rivera NV, Puca AA, Peschle C, Condorelli G (2010) Correlations between progression of coronary artery disease and circulating endothelial progenitor cells. FASEB J 24(6):1981–1988
10. Chen MC, Chen CJ, Yang CH, Liu WH, Fang CY, Hsieh YK, Chang HW (2008) Relationship of the percentage of circulating endothelial progenitor cell to the severity of coronary artery disease. Heart Vessels 23(1):47–52
11. Ma ZL, Mai XL, Sun JH, Ju SH, Yang X, Ni Y, Teng GJ (2009) Inhibited atherosclerotic plaque formation by local administration of magnetically labeled endothelial progenitor cells (EPCs) in a rabbit model. Atherosclerosis 205(1):80–86
12. Fadini GP, Agostini C, Sartore S, Avogaro A (2007) Endothelial progenitor cells in the natural history of atherosclerosis. Atherosclerosis 194(1):46–54
13. Wang X, Chen J, Tao Q, Zhu J, Shang Y (2004) Effects of ox-LDL on number and activity of circulating endothelial progenitor cells. Drug Chem Toxicol 27(3):243–255
14. Tie G, Yan J, Yang Y, Park BD, Messina JA, Raffai RL, Nowicki PT, Messina LM (2010) Oxidized low-density lipoprotein induces apoptosis in endothelial progenitor cells by inactivating the phosphoinositide 3-kinase/Akt pathway. J Vasc Res 47(6):519–530
15. Ma FX, Zhou B, Chen Z, Ren Q, Lu SH, Sawamura T, Han ZC (2006) Oxidized low density lipoprotein impairs endothelial progenitor cells by regulation of endothelial nitric oxide synthase. J Lipid Res 47(6):1227–1237
16. Sugiura T, Kondo T, Kureishi-Bando Y, Numaguchi Y, Yoshida O, Dohi Y, Kimura G, Ueda R, Rabelink TJ, Murohara T (2008) Nifedipine improves endothelial function: role of endothelial progenitor cells. Hypertension 52:491–498
17. Richardson MR, Yoder MC (2011) Endothelial progenitor cells: quo vadis? J Mol Cell Cardiol 50(2):266–272
18. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348(7):593–600
19. Schmidt-Lucke C, Rössig L, Fichtlscherer S, Vasa M, Britten M, Kämper U, Dimmeler S, Zeiher AM (2005) Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111:2981–2987
20. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig G (2005) Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353:999–1007
21. Bozdag-Turan I, Turan RG, Paranskaya L, Arsoy NS, Turan CH, Akin I, Kische S, Ortak J, Schneider H, Ludovicy S, Hermann T, D’Ancona G, Durdu S, Akar AR, Ince H, Nienaber CA (2012) Correlation between the functional impairment of bone marrow-derived circulating progenitor cells and the extend of coronary artery disease. J Transl Med 10:143
22. George J, Afek A, Abashidze A, Shmilovich H, Deutsch V, Kopolovich J, Miller H, Keren G (2005) Transfer of endothelial progenitor and bone marrow cells influences atherosclerotic plaque size and composition in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 25(12):2636–2641
23. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, Hirai H, Makuuchi M, Hirata Y, Nagai R (2002) Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 8(4):403–409
24. Min TQ, Zhu CJ, Xiang WX, Hui ZJ, Peng SY (2004) Improvement in endothelial progenitor cells from peripheral blood by ramipril therapy in patients with stable coronary artery disease. Cardiovasc Drugs Ther 18:203–209
25. Imanishi T, Moriwaki C, Hano T, Nishio I (2005) Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with essential hypertension. J Hypertens 23:1831–1837
26. Wang CH, Ciliberti N, Li SH, Szmitko PE, Weisel RD, Fedak PW, Al-Omran M, Cherng WJ, Li RK, Stanford WL, Verma S (2004) Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation 109:1392–1400
27. Pistrosch F, Herbrig K, Oelschlaegel U, Richter S, Passauer J, Fischer S, Gross P (2005) PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis 183:163–167
28. Fadini GP, de Kreutzenberg S, Albiero M, Coracina A, Pagnin E, Baesso I, Cignarella A, Bolego C, Plebani M, Nardelli GB, Sartore S, Agostini C, Avogaro A (2008) Gender differences in endothelial progenitor cells and cardiovascular risk profile: the role of female estrogens. Arterioscler Thromb Vasc Biol 28:997–1004
29. Toutain CE, Filipe C, Billon A, Fontaine C, Brouchet L, Guéry JC, Gourdy P, Arnal JF, Lenfant F (2009) Estrogen receptor alpha expression in both endothelium and hematopoietic cells is required for the accelerative effect of estradiol on reendothelialization. Arterioscler Thromb Vasc Biol 29(10):1543–1550
30. Chen TG, Chen JZ, Xie XD (2006) Effects of aspirin on number, activity and inducible nitric oxide synthase of endothelial progenitor cells from peripheral blood. Acta Pharmacol Sin 27(4):430–436
31. Hu Z, Zhang F, Yang Z, Zhang J, Zhang D, Yang N, Zhang Y, Cao K (2008) Low-dose aspirin promotes endothelial progenitor cell migration and adhesion and prevents senescence. Cell Biol Int 32(7):761–768
32. Ramirez R, Carracedo J, Nogueras S, Buendia P, Merino A, Cañadillas S, Rodríguez M, Tetta C, Martin-Malo A, Aljama P (2009) Carbamylated darbepoetin derivative prevents endothelial progenitor cell damage with no effect on angiogenesis. J Mol Cell Cardiol 47(6):781–788
33. Kawachi K, Iso Y, Sato T, Wakabayashi K, Kobayashi Y, Takeyama Y, Suzuki H (2012) Effects of erythropoietin on angiogenesis after myocardial infarction in porcine. Heart Vessels 27(1):79–88
34. Rabini RA, Galassi R, Fumelli P, Dousset N, Solera ML, Valdiguie P, Curatola G, Ferretti G, Taus M, Mazzanti L (1994) Reduced Na(+)-K(+)-ATPase activity and plasma lysophosphatidylcholine concentrations in diabetic patients. Diabetes 43:915–919
35. Chen L, Liang B, Froese DE, Liu S, Wong JT, Tran K, Hatch GM, Mymin D, Kroeger EA, Man RY, Choy PC (1997) Oxidative modification of low density lipoprotein in normal and hyperlipidemic patients: effect of lysophosphatidylcholine composition on vascular relaxation. J Lipid Res 38(3):546–553
36. Mannheim D, Herrmann J, Versari D (2008) Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke 39(5):1448–1455
37. Dohi T, Miyauchi K, Ohkawa R, Nakamura K, Kishimoto T, Miyazaki T, Nishino A, Nakajima N, Yaginuma K, Tamura H, Kojima T, Yokoyama K, Kurata T, Shimada K, Yatomi Y, Daida H (2012) Increased circulating plasma lysophosphatidic acid in patients with acute coronary syndrome. Clin Chim Acta 413(1–2):207–212
38. Dohi T, Miyauchi K, Ohkawa R, Nakamura K, Kurano M, Kishimoto T, Yanagisawa N, Ogita M, Miyazaki T, Nishino A, Yaginuma K, Tamura H, Kojima T, Yokoyama K, Kurata T, Shimada K, Daida H, Yatomi Y (2013) Increased lysophosphatidic acid levels in culprit coronary arteries of patients with acute coronary syndrome. Atherosclerosis 229(1):192–197
39. Oka H, Kugiyama K, Doi H, Matsumura T, Shibata H, Miles LA, Sugiyama S, Yasue H (2000) Lysophosphatidylcholine induces urokinase-type plasminogen activator and its receptor in human macrophages partly through redox-sensitive pathway. Arteriosclero Thromb Vasc Biol 20(1):244–250
40. Oestvang J, Johansen B (2006) PhospholipaseA2: a key regulator of inflammatory signalling and a connector to fibrosis development in atherosclerosis. Biochim Biophys Acta 1761(11):1309–1316
41. Massa M, Rosti V, Ferrario M, Campanelli R, Ramajoli I, Rosso R, De Ferrari GM, Ferlini M, Goffredo L, Bertoletti A, Klersy C, Pecci A, Moratti R, Tavazzi L (2005) Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 105(1):199–206
42. Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki K, Shimada T, Oike Y, Imaizumi T (2001) Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 103(23):2776–2779
43. Kakizaki M, Nobori K, Watanabe H, Iino K, Ishida M, Ito H (2013) Increased circulating CD3(+)/CD31 (+) T cells in patients with acute coronary syndrome. Heart Vessels 28(5):566–569
44. Takahashi M, Okazaki H, Ogata Y, Takeuchi K, Ikeda U, Shimada K (2002) Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen activated protein kinase-dependent mechanism. Atherosclerosis 161:387–394
45. Ozaki H, Ishii K, Arai H, Kume N, Kita T (1999) Lysophosphatidylcholine activates mitogen-activated protein kinases by a tyrosine kinase-dependent pathway in bovine aortic endothelial cells. Atherosclerosis 143:261–266
46. Fernández-Hernando C, Ackah E, Yu J, Suárez Y, Murata T, Iwakiri Y, Prendergast J, Miao RQ, Birnbaum MJ, Sessa WC (2007) Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease. Cell Metab 6(6):446–457
47. Lyon CA, Johnson JL, Williams H, Sala-Newby GB, George SJ (2009) Soluble N-cadherin overexpression reduces features of atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 29(2):195–201
48. Nakagawa K, Shibata A, Saito T, Sookwong P, Kato S, Tsuduki T, Matsubara K, Miyazawa T (2011) Phosphatidylcholine hydroperoxide promotes VEGF-induced angiogenesis in endothelial cells and rat aorta ring cultures. Biochim Biophys Acta 1810(12):1205–1211
49. Brunt KR, Fenrich KK, Kiani G, Tse MY, Pang SC, Ward CA, Melo LG (2006) Protection of human vascular smooth muscle cells from H2O2-induced apoptosis through functional codependence between HO-1 and AKT. Arterioscler Thromb Vasc Biol 26(9):2027–2034
50. Cheng J, Cui R, Chen CH, Du J (2007) Oxidized low-density lipoprotein stimulates p53-dependent activation of proapoptotic Bax leading to apoptosis of differentiated endothelial progenitor cells. Endocrinology 148(5):2085–2094
51. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rütten H, Fichtlscherer S, Martin H, Zeiher AM (2001) HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI3-kinase/Akt pathway. J Clin Invest 108(3):391–397
52. Yukihito H, Hidehiro M, Hidekazu U, Ryo S, Yuichi F, Junko S, Yasuki K, Kazuaki C, Tsutomu I (2010) Endothelial function in subjects with isolated low HDL cholesterol: role of nitric oxide and circulating progenitor cells. Am J Physiol Endocrinol Metab 298:E202–E209
53. Petra JM, Antonio JL, Pilar C, Priscila RM, Carlos M, Francisco JS, Guillermo M (2008) Pravastatin increases the expression of the tissue inhibitor of matrix metalloproteinase-1 and the oncogene Bax in human aortic abdominal aneurysms. Can J Physiol Pharmacol 86:431–437
54. Takahashi Y, Satoh M, Tabuchi T, Nakamura M (2012) Prospective, randomized, single-blind comparison of effects of 6 months’ treatment with atorvastatin versus pravastatin on leptin and angiogenic factors in patients with coronary artery disease. Heart Vessels 27(4):337–343
55. Serruys PW, García-García HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Bøtker HE, von Birgelen C, D’Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A, Integrated Biomarker and Imaging Study-2 Investigators (2008) Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118(11):1172–1182